Efficacy and Safety of Triple Antiplatelet Therapy With and Without Concomitant Anticoagulation During Elective Percutaneous Coronary Intervention (the REMOVE Trial)-Reference-Cited by-同舟云学术

Efficacy and Safety of Triple Antiplatelet Therapy With and Without Concomitant Anticoagulation During Elective Percutaneous Coronary Intervention (the REMOVE Trial)

Published:2007-10 Issue:7 Volume:100 Page:1099-1102
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Valencia Rafael,Price Matthew J.,Sawhney Neil,Lee Steve S.,Wong Garrett B.,Gollapudi Raghava R.,Banares Michelle,Schatz Richard A.,Teirstein Paul S.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference20 articles.

1. The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy;Landefeld;J Clin Epidemiol,1989

2. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy;Lancet,2000

3. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial;Lincoff;JAMA,2003

4. Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy;Denardo;Am Heart J,2005

5. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab;Cote;Mayo Clin Proc,2001

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary use of anticoagulation in the cardiac catheterization laboratory;Coronary Artery Disease;2021-08-17

2. Feasibility of coronary fractional flow reserve with dual anti-platelet therapy in low risk coronary lesions without systemic anticoagulation—results of the SMART—FFR study;Cardiovascular Revascularization Medicine;2018-04

3. The REDUCED (A R andomisED stU dy C omparing standard systemic anticoagulation thE rapy to low D ose intracoronary anticoagulation therapy for elective percutaneous coronary intervention) trial. A novel pharmacologic regime for elective percutaneous coronary intervention;Acta Cardiologica;2014-12

4. Comparison of Bolus Only With Bolus Plus Infusion of Bivalirudin in Patients Undergoing Elective Percutaneous Coronary Intervention: A Retrospective Observational Study;Journal of Pharmacy Practice;2012-05-09

5. Unfractionated Heparin during Elective PCI: Fixed Dose or Weight Adjusted?;Cardiovascular Therapeutics;2010-10-14